MX2020000636A - Proteinas sinteticas y usos terapeuticos de las mismas. - Google Patents

Proteinas sinteticas y usos terapeuticos de las mismas.

Info

Publication number
MX2020000636A
MX2020000636A MX2020000636A MX2020000636A MX2020000636A MX 2020000636 A MX2020000636 A MX 2020000636A MX 2020000636 A MX2020000636 A MX 2020000636A MX 2020000636 A MX2020000636 A MX 2020000636A MX 2020000636 A MX2020000636 A MX 2020000636A
Authority
MX
Mexico
Prior art keywords
synthetic proteins
therapeutic uses
disclosure relates
proteins
synthetic
Prior art date
Application number
MX2020000636A
Other languages
English (en)
Inventor
Keith Alan Charlton
Erik D''HONDT
Original Assignee
In3Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by In3Bio Ltd filed Critical In3Bio Ltd
Publication of MX2020000636A publication Critical patent/MX2020000636A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente divulgacion se refiere a composiciones y metodos para tratar la enfermedad. Mas particularmente, la divulgacion se refiere a las proteinas sinteticas y su uso para tratar el cancer.
MX2020000636A 2017-07-18 2018-07-18 Proteinas sinteticas y usos terapeuticos de las mismas. MX2020000636A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533901P 2017-07-18 2017-07-18
PCT/IB2018/000898 WO2019016597A2 (en) 2017-07-18 2018-07-18 SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES

Publications (1)

Publication Number Publication Date
MX2020000636A true MX2020000636A (es) 2020-08-20

Family

ID=63857968

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000636A MX2020000636A (es) 2017-07-18 2018-07-18 Proteinas sinteticas y usos terapeuticos de las mismas.

Country Status (12)

Country Link
US (1) US20210009716A1 (es)
EP (1) EP3655025A2 (es)
JP (1) JP2020527579A (es)
KR (1) KR20200029010A (es)
CN (1) CN111246878A (es)
AU (1) AU2018304957A1 (es)
BR (1) BR112020001045A2 (es)
CA (1) CA3070034A1 (es)
IL (2) IL300235A (es)
MX (1) MX2020000636A (es)
RU (1) RU2020106669A (es)
WO (1) WO2019016597A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112996534A (zh) 2018-08-07 2021-06-18 因斯瑞拜奥有限公司 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物
JP2022539067A (ja) * 2019-06-25 2022-09-07 イン３バイオ・リミテッド 安定化キメラ合成タンパク質及びその治療的使用
WO2023073429A1 (en) 2021-10-28 2023-05-04 In3Bio Ltd. Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
BRPI0010612B8 (pt) 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vacinas
CU22999A1 (es) 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
JP4623625B2 (ja) * 2003-07-24 2011-02-02 株式会社ＡＭＢｉＳ ヘテロ型５量体組換えワクチン
US8247531B2 (en) * 2006-03-20 2012-08-21 Cochran Jennifer R Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
CN104066447A (zh) * 2011-11-23 2014-09-24 拜奥文斯瑞有限公司 重组蛋白及其治疗用途
EP2970409A2 (en) * 2013-03-15 2016-01-20 Bioven 3 Limited Self-assembling synthetic proteins
SI3345613T1 (sl) * 2015-09-01 2023-10-30 Il Dong Pharmaceutical Co., Ltd. Sestavek za uporabo pri zdravljenju raka ali z angiogenezo povezane bolezni, ki obsega fuzijski protein iz tumor-penetrirajočega peptida in sredstva anti-VEGF

Also Published As

Publication number Publication date
CN111246878A (zh) 2020-06-05
IL272050B1 (en) 2023-03-01
AU2018304957A1 (en) 2020-02-13
BR112020001045A2 (pt) 2020-09-08
WO2019016597A3 (en) 2019-04-18
IL272050B2 (en) 2023-07-01
RU2020106669A3 (es) 2022-04-07
JP2020527579A (ja) 2020-09-10
KR20200029010A (ko) 2020-03-17
IL272050A (en) 2020-03-31
RU2020106669A (ru) 2021-08-18
US20210009716A1 (en) 2021-01-14
EP3655025A2 (en) 2020-05-27
CA3070034A1 (en) 2019-01-24
WO2019016597A2 (en) 2019-01-24
IL300235A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2019012233A (es) Anticuerpos anti-sirpa.
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
MX2022007522A (es) Anticuerpos anti-cd27.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
NZ738008A (en) Tigit-binding agents and uses thereof
MX2017003211A (es) Anticuerpos anti-met y composiciones.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2017009608A (es) Compuestos anticancerigenos.
MX2021015922A (es) Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos.
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci